drugset / Trial / NCT04469127
A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.
Phase 1/2
Unknown
100 enrolled
Advanced Imaging Projects, LLC
Postgraduate Institute of Medical and Research · collabUniversity of Witwatersrand, South Africa · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a Phase I/II clinical evaluation of a new investigational agent, Lutetium-177-DOTAGA-IAC (HurlutinTM Lu-177) to treat patients with unresectable angiogenic breast cancer who have previously been treated with at least one prior line of therapy.
Timeline
- Start
- 2024-09-30
- Primary completion
- 2025-08-30
- Completion
- 2025-08-30
Publications
- Results Baum RP, Kulkarni HR, Muller D, Satz S, Danthi N, Kim YS, Brechbiel MW. First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for alphavbeta3 Integrin Receptor Targeting. Cancer Biother Radiopharm. 2015 May;30(4):152-9. doi: 10.1089/cbr.2014.1747.
- Results Kim YS, Nwe K, Milenic DE, Brechbiel MW, Satz S, Baidoo KE. Synthesis and characterization of alphavbeta(3)-targeting peptidomimetic chelate conjugates for PET and SPECT imaging. Bioorg Med Chem Lett. 2012 Sep 1;22(17):5517-22. doi: 10.1016/j.bmcl.2012.07.024. Epub 2012 Jul 14.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lutetium-177-DOTAGA-IAC | Unknown | 100 ug | Other |
| Subject | Lutetium-177-DOTAGA-IAC | Unknown | 2775 mbq | Other |
| Subject | Lutetium-177-DOTAGA-IAC | Unknown | 5550 mbq | Other |
| Subject | Lutetium-177-DOTAGA-IAC | Unknown | 7400 mbq | Other |